Chamber and committees

The Scottish Government fully understands the pressures that hospices are currently facing. The Minister for Public Health and Women’s Health engages regularly with this sector, and has visited a number of hospices and met with hospice leaders over the last few months.

Integration Joint Boards are responsible for the planning, and commissioning of adult palliative care services, including hospices, using the integrated budget under their control. We have invested over £2 billion in the 2024-25 budget for social care and integration, delivering on our Programme for Government commitment to increase social care spending by 25% over this Parliament. Despite this significant investment the financial climate remains extremely challenging and we are working with partners to understand and address the challenges, within the context of a finite budget.

Access to continuing professional development and education for community children’s nursing staff in Scotland is vital as it enables children to receive specialist care within a setting that is familiar and comforting to them. However, it is the responsibility of higher education institutions to develop and deliver education at Masters level. It is the Scottish Government’s understanding that Robert Gordon University have developed a contemporary Specialist Practitioner Qualification in community children's nursing, at Masters level, which will be presented for approval by the Nursing and Midwifery Council at the end of May this year. If approved, the programme will move forward with a provisional starting date of September 2024.

The information requested on how many community children’s nurses are employed by NHS Scotland, broken down by NHS board can be found on the TURAS NHS Education for Scotland workforce statistics site at: 05 March 2024 Workforce | Turas Data Intelligence (nhs.scot)

The Scottish Government has commissioned NHS National Services Scotland to work with a wide range of clinical and other stakeholders to consider how best to meet the needs of the population in terms of young people’s gender healthcare services for NHS Scotland. This work is ongoing, and aims to define the scope of a specialist service in Scotland.

The Scottish Government anticipates that an outline service specification based on this work will be presented to NHS Strategic Planning Board for Scotland for consideration later this year.

The term “puberty-suppressing hormones” is non-specific, and could be applied to a range of medicines used for a variety of conditions.

In the context of the provision of gender identity healthcare to children and young people, I refer the member to question S6O-03286 on 28 March 2024. which is available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/official-report/search-what-was-said-in-parliament .

The Scottish Government does not routinely hold or collate this information. This information should be requested from the relevant Health Boards.

The Scottish Government understands that Public Health Scotland intends to publish, as official statistics in development, gender identity clinic waiting times information provided by NHS Grampian, NHS Greater Glasgow and Clyde, NHS Highland and NHS Lothian in late summer 2024. This will be subject to the necessary data quality and completeness standards being met.

The Scottish Government welcomes the publication, on 10 April, of the final report and recommendations of the NHS England-commissioned Independent Review of Gender Identity Services for Children and Young People, chaired by Dr Hiliary Cass (‘the Cass Review’).

The findings of the review, and the associated systematic review papers, are being closely considered by both the Scottish Government and Health Boards in Scotland in the context of how such healthcare is best delivered here.

On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.

The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.

Decisions on clinical pathways are not for the Scottish Government. These decisions are for clinicians, based on the best evidence available, through the appropriate clinical governance structures.

The Scottish Government is unaware of any discussions between NHS Scotland Health Boards and the UK Government regarding the prescription of puberty-suppressing hormones as a treatment option for gender dysphoria.

The National Gender Identity Healthcare Reference Group continues to meet and make progress against all the commitments set out within the referenced December 2021 Strategic Action Framework. This includes:

• Healthcare Improvement Scotland developing standards for gender identity healthcare for NHS Scotland;
• NHS Education Scotland developing a Transgender Health Knowledge and Skills framework for NHS staff;
• Public Health Scotland working with Health Boards to deliver publication of waiting times data by them; and
• Grant funding to the University of Glasgow to administer a programme of research on gender identity healthcare.

The term “puberty-suppressing hormones” is non-specific, and could be applied to a range of medicines used for a variety of conditions.

The Scottish Government and NHS Scotland are proactively engaged with NHS England and its commissioned research study on puberty-suppressing hormones as a treatment option for gender dysphoria. This is being delivered by the National Institute for Health Research (NIHR). The Scottish Government and the NHS in Scotland are currently observers to that ongoing study development process, however consideration by NHS partners of what further engagement with this study may be appropriate is ongoing, as the scope of the research continues to be developed and defined by NIHR.